- Home
- CGC vs PGEN Comparison
CGC vs PGEN Comparison
Compare CGC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- PGEN
- Stock Information
- Founded
- CGC N/A
- PGEN 1998
- Country
- CGC Canada
- PGEN United States
- Employees
- CGC N/A
- PGEN N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CGC Health Care
- PGEN Health Care
- Exchange
- CGC Nasdaq
- PGEN Nasdaq
- Market Cap
- CGC 431.7M
- PGEN 493.0M
- IPO Year
- CGC N/A
- PGEN N/A
- Fundamental
- Price
- CGC $1.46
- PGEN $4.36
- Analyst Decision
- CGC Hold
- PGEN Buy
- Analyst Count
- CGC 1
- PGEN 5
- Target Price
- CGC N/A
- PGEN $7.50
- AVG Volume (30 Days)
- CGC 33.7M
- PGEN 18.2M
- Earning Date
- CGC 08-08-2025
- PGEN 08-12-2025
- Dividend Yield
- CGC N/A
- PGEN N/A
- EPS Growth
- CGC N/A
- PGEN N/A
- EPS
- CGC N/A
- PGEN N/A
- Revenue
- CGC $201,572,742.00
- PGEN $4,340,000.00
- Revenue This Year
- CGC $13.24
- PGEN $253.63
- Revenue Next Year
- CGC $3.68
- PGEN $699.64
- P/E Ratio
- CGC N/A
- PGEN N/A
- Revenue Growth
- CGC N/A
- PGEN N/A
- 52 Week Low
- CGC $0.77
- PGEN $0.65
- 52 Week High
- CGC $5.80
- PGEN $5.23
- Technical
- Relative Strength Index (RSI)
- CGC 52.64
- PGEN 71.16
- Support Level
- CGC $1.31
- PGEN $4.41
- Resistance Level
- CGC $1.93
- PGEN $5.23
- Average True Range (ATR)
- CGC 0.15
- PGEN 0.41
- MACD
- CGC -0.01
- PGEN 0.06
- Stochastic Oscillator
- CGC 39.74
- PGEN 66.67
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.